Setback for Trovax in pivotal renal cancer study
This article was originally published in Scrip
Oxford BioMedica's lead investigational product Trovax, a novel therapeutic cancer vaccine which is being developed with Sanofi-Aventis, will not meet its predefined primary endpoint of a survival benefit in its pivotal Phase III study in its lead indication of renal cancer, the study's data safety monitoring board advised the company after conducting a fourth interim analysis.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.